Market Outlook—Market Performance and IPO Class of 2020

4:00 PM - 4:55 PM (EST), Tuesday, February 11, 2020 ・ Lyceum Complex
With the close out of 2019 at record levels and 2020 in full swing, the biotechnology sector has proven itself to be a rewarding place for investors to devote their capital. The nature of the industry has also continually driven investors’ focus toward the long-term potential, rather than short-term gains. While 2018 witnessed biotechnology companies going public at a frantic pace, 2019 brought more hesitation due to the pre- and post-IPO price volatility and the availability of robust private capital earlier in the company lifecycle. This access to capital has allowed companies to maintain focus on the R&D product pipeline and build mature enterprises with established clinical results prior to accessing the public markets. With a strong market economy and healthy portfolio of large, private companies, it begs the question of whether the overall market will experience a cooling off period in 2020 or if we are at the beginning of a long-term growth cycle? This session will examine the path forward while highlighting the availability of quality targets in the market.
Senior Biotechnology Analyst
Zacks Research
Managing Director
Cantor Fitzgerald
Managing Director, Investment Banking
H.C. Wainwright & Co. , LLC
CEO and Co-Founder
American Gene Technologies
Managing Director, Biotechnology Analyst
Mizuho Securities
H.I.G. BioHealth Partners